Search research articles
Contact Us
Filters
Showing results (81-90 of 88) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 88 results.
The New England Journal of Medicine
|
December 17, 2020
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
The Journal of Infectious Diseases
|
July 27, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, et al.
The Lancet. Infectious Diseases
|
July 8, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
Gary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al.
The New England Journal of Medicine
|
September 29, 2021
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
The New England Journal of Medicine
|
August 4, 2021
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
Meagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 23, 2021
Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention
Meagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, et al.
JAMA
|
January 14, 2022
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
Meagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 23, 2021
Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
Meagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 88) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 88 results.
The New England Journal of Medicine
|
December 17, 2020
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
The Journal of Infectious Diseases
|
July 27, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, et al.
The Lancet. Infectious Diseases
|
July 8, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
Gary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al.
The New England Journal of Medicine
|
September 29, 2021
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
The New England Journal of Medicine
|
August 4, 2021
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
Meagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 23, 2021
Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention
Meagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, et al.
JAMA
|
January 14, 2022
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
Meagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 23, 2021
Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
Meagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.
Page
of 9